glp-1 intracranial hypertension Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine Scientists discover common obesity and

Semaglutide should not typically be combined with other medications that act on the same GLP-1 pathway, such as tirzepatide or other GLP-1 receptor agonists

This impressive weight reduction with the various long-acting gut peptide-based therapies is largely believed to result from a reduced food/calorie intake, which results from decreased appetite and earlier and increased satiety, coupled with controlled and mindful eating

While universal deprescribing is unlikely to drive optimal results, it may make sense on an individual basis to explore discontinuation, lowering the dose, or increasing time between doses, as patients enter a maintenance phase with their treatment

Common ratios: 5 mg in 2 mL gives 2,500 mcg/mL

These findings further support CRAT as a critical tumor suppressor in carcinogenesis and metastasis of OC